Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arjo ABARRJF -0.34%74 3-1 Month Momentum % is -7.93% as of Aug. 17, 2026. GuruFocus rates ARRJF with a GF Score™ of 74/100 and a GF Value™ of $3.51 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 123 Medical Distribution companies, Arjo AB ranks better than 73.17% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-17), Arjo AB's 3-1 Month Momentum % is -7.93%.
The industry rank for Arjo AB's 3-1 Month Momentum % or its related term are showing as below:
ARRJF's 3-1 Month Momentum % is ranked better than 73.17% of 123
companies
in the Medical Distribution industry
Industry Median: -2.16
vs ARRJF: -7.93
Arjo AB (OTCPK:ARRJF) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Arjo AB 3-1 Month Momentum % Related Terms
ARRJF vs MCK, COR, CAH: 3-1 Month Momentum % Comparison
For the Medical Distribution subindustry, Arjo AB's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arjo AB 3-1 Month Momentum % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Arjo AB's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Arjo AB's 3-1 Month Momentum % falls into.
Arjo AB (OTCPK:ARRJF) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arjo AB (ARRJF) has a 3-1 Month Momentum % of -7.93% as of Aug. 17, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Arjo AB and its competitors. According to the industry distribution chart, Arjo AB ranks #33 out of 123 companies in the Medical Distribution industry, placing it in the top 26.8%.
Is Arjo AB's 3-1 Month Momentum % too high?
Arjo AB's current 3-1 Month Momentum % is -7.93%. Based on the distribution chart, Arjo AB ranks #33 out of 123 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Arjo AB has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Arjo AB's 3-1 Month Momentum % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Arjo AB ranks #33 out of 123 companies for 3-1 Month Momentum %. This puts Arjo AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Distribution company?
A good 3-1 Month Momentum % depends on the Medical Distribution industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Arjo AB and its competitors. Arjo AB's current 3-1 Month Momentum % is -7.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arjo AB stock overvalued right now?
Based on GuruFocus' analysis, Arjo AB (ARRJF) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.51, compared to a current price of $2.91 — trading 17.1% below its estimated fair value. The current 3-1 Month Momentum % is -7.93%. Arjo AB's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Arjo AB (ARRJF), the current 3-1 Month Momentum % is -7.93% as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arjo AB (ARRJF) Overvalued in 2026?
Based on GuruFocus' analysis, Arjo AB stock appears to be undervalued.
The current stock price of $2.91 is trading 17.1% below its estimated GF Value™ of $3.51.
GuruFocus considers Arjo AB to be Modestly Undervalued.
Key valuation signals for ARRJF:
3-1 Month Momentum %: -7.93%
GF Value™: $3.51 vs. price of $2.91 (17.1% below fair value)
No single metric tells the full story. See the ARRJF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arjo AB is a supplier of medical devices, services, and solutions in Sweden. It serves its services to private and public institutions with acute care and long-term care. The company's offering includes products and solutions for patient handling, hygiene, disinfection, medical beds, therapeutic surfaces, venous thromboembolism (VTE) prevention and diagnostics. The company includes segments: Global Sales, North America, Diagnostics.
74GF Score
Get the complete analysis for ARRJF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARRJF has been successfully added to your 
